Study identifier:D5161R00017
ClinicalTrials.gov identifier:NCT05103605
EudraCT identifier:N/A
CTIS identifier:N/A
Positioning, utilization and effectiveness of osimertinib in first line in real-life therapeutic strategy in France Prospective Cohort of Locally Advanced and Metastatic Non-Small Cell Lung Cancer Patients with activating EGFR Mutations
Non Small Cell Lung Cancer
N/A
No
Osimertinib
All
274
Observational
18 Years - n/a
Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Jun 2024 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|